Bayerisches Zentrum für Krebsforschung (BZKF)

Research / Science organisation


Location: Erlangen, Germany (DE) DE


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Sex-Dependent T Cell Dysregulation in Mice with Diet-Induced Obesity (2024) Brummer C, Singer K, Brand A, Bruss C, Renner K, Herr W, Pukrop T, et al. Journal article Gene network-based and ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapy (2024) Lischer C, Eberhardt M, Flamann C, Berges J, Güse E, Wessely A, Weich A, et al. Journal article Human-Level Differentiation of Medulloblastoma from Pilocytic Astrocytoma: A Real-World Multicenter Pilot Study (2024) Wiestler B, Bison B, Behrens L, Tüchert S, Metz M, Griessmair M, Jakob M, et al. Journal article Correlation of RANK and RANKL with mammographic density in primary breast cancer patients (2024) Wunderle M, Heindl F, Behrens A, Häberle L, Hack C, Heusinger K, Hübner H, et al. Journal article Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion (2023) Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bücklein VL, Völkl S, Penack O, et al. Journal article Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance (2023) Klümper N, Ralser DJ, Ellinger J, Roghmann F, Albrecht J, Below E, Alajati A, et al. Journal article Identifying Early Infections in the Setting of CRS with Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL (2023) Rejeski K, Blumenberg V, Iacoboni G, Lopez-Corral L, Kharboutli S, Hernani R, Petrera A, et al. Journal article CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial (2023) Mackensen A, Haanen JB, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, Heudobler D, et al. Journal article PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma (2023) Klümper N, Wüst L, Saal J, Ralser DJ, Zarbl R, Jarczyk J, Breyer J, et al. Journal article The future of affordable cancer immunotherapy (2023) Schaft N, Dörrie J, Schuler G, Schuler-Thurner B, Sallam H, Klein S, Eisenberg G, et al. Journal article, Review article